panitumumab
takeda,amgen
['triplet', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)']
 presentation #asco22 triplette, but no benefit in any study endpoint with folfoxiri +pan c/w folfox +pan in 1st line ras/braf wt mcrc incl metastatic resection rates
differ from volfi phase 2 lower dose of fu in experimental arm folfoxiri/pan not soc 
Optimist. GI medical oncologist. Coffee, Irn-Bru & dog enthusiast @foxtrotstudy @focus4trial @ArielTrial #pelotonuk ??????????? ????